The 2026 amendment adds 40 new recommendations, including active surveillance, office-based treatment, and chemoablation for select recurrent low-grade disease.
Related to this article
The FDA approved lirafugratinib in FGFR2+ cholangiocarcinoma and belzutifan plus lenvatinib in advanced ccRCC, and more.
Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.
FDA grants priority review to durvalumab plus enfortumab vedotin for cisplatin-ineligible MIBC based on positive phase 3 VOLGA data.
Advertisement
Advertisement
Trending on OncLive
1
‘Our Impact Will Be Broad and Transformative’: Wells Messersmith, MD, Takes the Reins at CU Anschutz Cancer Center
2
NDA Submission Is Initiated for Zipalertinib Plus Chemotherapy in Frontline EGFR Exon 20 Insertion+ NSCLC
3
The OncFive: Top Oncology Articles for the Week of 9/27/2026
4
Oral Azacitidine and Cedazuridine Meets Primary Pharmacokinetic End Point in MDS and CMML
5